China-based Suzhou Ribo Life Science Co Ltd (HK:06938) and Sweden-based Ribocure Pharmaceuticals AB (together 'Ribo') announced on Wednesday the submission of a Phase 2 clinical trial application to the European Medicines Agency (EMA) for RBD1119, a siRNA based therapeutic for the treatment of coronary artery disease.
Ribo has been advancing multiple siRNA candidates in parallel across atrial fibrillation and venous thromboembolism, and has established an anticoagulation/antithrombotic pipeline.
This new submission for coronary artery disease represents a key milestone in Ribo's programme to advance innovative oligonucleotide-based therapies aimed at systematically addressing the root cause of thromboembolic diseases.
IceCure reports growing adoption of ProSense cryoablation in Brazil
Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis
Genentech reports positive Phase III results for divarasib in KRAS G12C lung cancer
Neurocrine Biosciences initiates crinecerfont Phase 2 study in young children with classic CAH
PharmaResearch to acquire CG USA to support North American expansion of REJURAN Cosmetics
Hansa Biopharma closes EUR115m Licensing Deal with SERB Pharmaceuticals for Idefirix
SciBase submits FDA filing to expand Nevisense use to non‑melanoma skin cancers
Galderma receives FDA Complete Response Letter for RelabotulinumtoxinA US filing
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
genedrive partners with Thermo Fisher Scientific to develop high-throughput CYP2C19 test